Prognostic Value of the Hippo Pathway Transcriptional Coactivators YAP/TAZ and β1-integrin in Conventional Osteosarcoma

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Sep 10

PMID 27608849

Citations 37

Authors

Corinne Bouvier

Nicolas Macagno

Quy Nguyen

Anderson Loundou

Carine Jiguet-Jiglaire

Jean-Claude Gentet

Jean-Luc Jouve

Alexandre Rochwerger

Jean-Camille Mattei

Daniel Bouvard

Sebastien Salas

Affiliations

Soon will be listed here.

Abstract

Introduction: Currently, very few studies are available concerning the mammalian Hippo pathway in bone sarcomas. YAP/TAZ transcription co-activators are key downstream effectors of this pathway and may also have oncogenic properties. Additionally, recent in-vitro experiments showed that expression of β1-integrin promoted metastasis in osteosarcomas. This study investigated the expression of YAP/TAZ and β1-integrin in human osteosarcomas.

Materials And Methods: We performed automated immunohistochemistry on tissue-microarrays (TMA) in which 69 conventional osteosarcomas biopsies performed prior to chemotherapy were embedded. Cellular localization and semi-quantitative analysis of each immunostain was performed using Immunoreactive Score (IRS) and correlated to clinico-pathological data.

Results: Cytoplasmic expression of β1-integrin was noted in 54/59 osteosarcomas (92%), with 33/59 cases (56%) displaying membranous staining. YAP/TAZ was expressed in 27/45 osteosarcomas (60%), with 14 cases (31%) showing cytoplasmic expression while 13 other cases (28%) displayed nuclear expression. No link was found between YAP/TAZ or β1-integrin expression and response to chemotherapy. In univariate analysis, YAP/TAZ immunoreactive score was pejoratively correlated with overall survival (p = 0.01). Expression of β1-integrin on cell membrane was also pejorative for OS (p = 0.045). In multivariate analysis, YAP/TAZ nuclear expression was an independent prognostic factor for PFS (p = 0.035).

Conclusion: this study indicates that β1-integrin and YAP/TAZ proteins are linked to prognosis and therefore could be therapeutic targets in conventional osteosarcomas.

Citing Articles

Signal Pathways and microRNAs in Osteosarcoma Growth and the Dual Role of Mesenchymal Stem Cells in Oncogenesis.

Todosenko N, Khlusov I, Yurova K, Khaziakhmatova O, Litvinova L Int J Mol Sci. 2023; 24(10).

PMID: 37240338 PMC: 10219319. DOI: 10.3390/ijms24108993.

Low p16 Cytoplasmic Staining Predicts Poor Treatment Outcome in Patients with p16-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving TPF Induction Chemotherapy.

Chen Y, Chien C, Huang T, Chiu T, Wang Y, Fang F Biomedicines. 2023; 11(2).

PMID: 36830875 PMC: 9953595. DOI: 10.3390/biomedicines11020339.

Genetic Alterations and Deregulation of Hippo Pathway as a Pathogenetic Mechanism in Bone and Soft Tissue Sarcoma.

Salguero-Aranda C, Olmedo-Pelayo J, de Alava E, Amaral A, Diaz-Martin J Cancers (Basel). 2022; 14(24).

PMID: 36551696 PMC: 9776600. DOI: 10.3390/cancers14246211.

Single-Cell Transcriptome Analysis Reveals Paraspeckles Expression in Osteosarcoma Tissues.

Rothzerg E, Feng W, Song D, Li H, Wei Q, Fox A Cancer Inform. 2022; 21:11769351221140101.

PMID: 36507075 PMC: 9730017. DOI: 10.1177/11769351221140101.

A calpain-6/YAP axis in sarcoma stem cells that drives the outgrowth of tumors and metastases.

Tchicaya-Bouanga J, Hung Y, Schwartz J, Yoon D, Chotard E, Marty C Cell Death Dis. 2022; 13(9):819.

PMID: 36153320 PMC: 9509353. DOI: 10.1038/s41419-022-05244-3.

References

Fullenkamp C, Hall S, Jaber O, Pakalniskis B, Savage E, Savage J . TAZ and YAP are frequently activated oncoproteins in sarcomas. Oncotarget. 2016; 7(21):30094-108. PMC: 5058666. DOI: 10.18632/oncotarget.8979. View

Banai K, Brady K, McDonald F . A preliminary optical and electron microscopic study of the beta(1) integrin distribution pattern of human osteosarcoma-derived cells. Histochem Cell Biol. 2004; 122(1):75-80. DOI: 10.1007/s00418-004-0663-3. View

Tang Y, Rowe R, Botvinick E, Kurup A, Putnam A, Seiki M . MT1-MMP-dependent control of skeletal stem cell commitment via a β1-integrin/YAP/TAZ signaling axis. Dev Cell. 2013; 25(4):402-16. PMC: 3736823. DOI: 10.1016/j.devcel.2013.04.011. View

Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Baum R . Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol. 2012; 5(3):187-94. PMC: 3341681. View

Yang Z, Zhang M, Xu K, Liu L, Hou W, Cai Y . Knockdown of YAP1 inhibits the proliferation of osteosarcoma cells in vitro and in vivo. Oncol Rep. 2014; 32(3):1265-72. DOI: 10.3892/or.2014.3305. View

Hong J, Yaffe M . TAZ: a beta-catenin-like molecule that regulates mesenchymal stem cell differentiation. Cell Cycle. 2006; 5(2):176-9. DOI: 10.4161/cc.5.2.2362. View

Yu F, Zhao B, Guan K . Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell. 2015; 163(4):811-28. PMC: 4638384. DOI: 10.1016/j.cell.2015.10.044. View

Lo V, Akens M, Wise-Milestone L, Yee A, Wilson B, Whyne C . The benefits of photodynamic therapy on vertebral bone are maintained and enhanced by combination treatment with bisphosphonates and radiation therapy. J Orthop Res. 2013; 31(9):1398-405. DOI: 10.1002/jor.22373. View

Liu-Chittenden Y, Huang B, Shim J, Chen Q, Lee S, Anders R . Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012; 26(12):1300-5. PMC: 3387657. DOI: 10.1101/gad.192856.112. View

10.

Huggett M, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M . Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014; 110(7):1698-704. PMC: 3974098. DOI: 10.1038/bjc.2014.95. View

11.

Hsu J, Lawlor E . BMI-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma. Oncogene. 2010; 30(17):2077-85. PMC: 3276065. DOI: 10.1038/onc.2010.571. View

12.

Remmele W, Stegner H . [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987; 8(3):138-40. View

13.

Johnson R, Halder G . The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 2013; 13(1):63-79. PMC: 4167640. DOI: 10.1038/nrd4161. View

14.

Pan D . The hippo signaling pathway in development and cancer. Dev Cell. 2010; 19(4):491-505. PMC: 3124840. DOI: 10.1016/j.devcel.2010.09.011. View

15.

Zender L, Spector M, Xue W, Flemming P, Cordon-Cardo C, Silke J . Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006; 125(7):1253-67. PMC: 3026384. DOI: 10.1016/j.cell.2006.05.030. View

16.

Chan L, Wang W, Yeung W, Deng Y, Yuan P, Mak K . Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression. Oncogene. 2013; 33(40):4857-66. DOI: 10.1038/onc.2013.433. View

17.

Kimura H, Tome Y, Momiyama M, Hayashi K, Tsuchiya H, Bouvet M . Imaging the inhibition by anti-β1 integrin antibody of lung seeding of single osteosarcoma cells in live mice. Int J Cancer. 2012; 131(9):2027-33. DOI: 10.1002/ijc.27475. View

18.

Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M . Role of YAP/TAZ in mechanotransduction. Nature. 2011; 474(7350):179-83. DOI: 10.1038/nature10137. View

19.

Avruch J, Zhou D, Fitamant J, Bardeesy N . Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development. Br J Cancer. 2010; 104(1):24-32. PMC: 3039822. DOI: 10.1038/sj.bjc.6606011. View

20.

Carvalho R, Scott J, Yen E . The effects of mechanical stimulation on the distribution of beta 1 integrin and expression of beta 1-integrin mRNA in TE-85 human osteosarcoma cells. Arch Oral Biol. 1995; 40(3):257-64. DOI: 10.1016/0003-9969(95)98814-f. View